Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results

Gelijkaardige items

• Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
  door: Freeman, Hugh J
  Gepubliceerd in: (2013)
• Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
  door: Kim, Jae Hyun, et al.
  Gepubliceerd in: (2016)
• Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
  door: Colombel, Jean-Frederic, et al.
  Gepubliceerd in: (2014)
• Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
  door: Suzuki, Yasuo, et al.
  Gepubliceerd in: (2013)
• Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
  door: Suzuki, Yasuo, et al.
  Gepubliceerd in: (2017)